Press Room

News / Oct 01, 2014

Hovione Cork – New General Manager - Paul Downing – since 1st October 2014

Paul joined Hovione on the 1st of October 2014. He holds a BSc in Chemical and Pharmaceutical Science from the University of Sunderland (UK) and a PhD in Organic Chemistry (asymmetric synthesis using organometallics) from Sheffield University (UK). He started his industrial career with Fisons Pharmaceuticals in Loughborough, where he worked in the R&D Analytical Laboratory. In early 1997, Paul joined Ciba-Geigy in Grimsby as a Process Chemist in the Chemical Operations area (Ciba-Geigy merged with Sandoz at that time and became Novartis later in 1997). He subsequently held several senior lead roles in both Quality and Production with Novartis. In 2007 he moved to New York to head up the Operations Unit  for Pharmaceutical Operations. As a result of Paul’s success in this function he was asked, in 2009, to take on the role of Global Head of Pharmaceutical Operations Strategy for Technical Operations at Head Office in Basel, where he stayed until 2012. Paul then chose to return to Cork with his family  and was invited by Chanelle Group to become Director of Operations near Galway.

Paul brings to Hovione over 20 years of relevant experience of development, quality, APIs manufacturing and formulation, as well as pharma strategy with Novartis and Chanelle. He also has considerable expertise in operational efficiency and world-class team leadership in pharma operations.

 

Hovione Cork - click here

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026